Metabolic · HGH C-terminal fragment (research)
AOD-9604
- Drug class
- HGH C-terminal fragment (research)
- Status
- Compounded (503A)
- Reviewed
- 2026-06-01 · Kindr Health Clinical Team
What AOD-9604 is studied for
- Fat metabolism and lipolysis (preclinical and small human trials)
- Cartilage repair research
- Body composition support
Mechanism of action
Mimics the lipolytic C-terminus of HGH without binding the growth hormone receptor. Stimulates fat breakdown and inhibits lipogenesis without affecting blood glucose or IGF-1 levels.
Frequently asked questions
Does AOD-9604 cause weight loss?
Human trials (Metabolic Pharmaceuticals, phase 2) showed modest weight loss vs. placebo over 12–24 weeks — meaningfully less than GLP-1 medications.
How is it dosed?
Daily subcutaneous injection (commonly 250–500 mcg/day, often morning, fasted). Cycled in most protocols.
Side effects?
Generally well tolerated in trials. Mild injection-site reactions; no significant impact on glucose, insulin, or IGF-1.
Is it FDA-approved?
No. Original obesity development was discontinued. It is sometimes used in compounded form for body-composition support.
Build the AOD-9604 protocol stack
Research protocols commonly pair AOD-9604 with the peptides below. Add all three vials to unlock the bundle discount at checkout.
Related peptides in Metabolic
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- GLP-1s in menopauseJournal
- Menopause & weight gainJournal
- SemaglutidePeptide
- TirzepatidePeptide
- GLP-1 weight care serviceMedication
